Weekly update Companies AI-cruiter Recruiting

Inozyme Pharma

Founded: 2016

Location: Boston, MA

Employee range: 11 - 50

Clinical stage: Clin1b/Clin2

Therapy area: ENPP1 deficiency

Drug types: GEN, RAR, CVV, PED

Lead product: INZ-701

Product link: https://www.inozyme.com/pipeline/our-science

Funding: $64.5M stock Aug 2023; $73M stock Apr 2022; $129M IPO Jul 2020; $67M A-2 Apr 2019; $49M A Nov 2017

Investors: Pivotal bioVenture Partners, Sofinnova Investment, RA Capital Management, Cowen Healthcare Investments, Rock Springs Capital, Longitude Capital, NEA, Novo Holdings, Sanofi Ventures

inozyme.com

linkedin.com

job board

Short description:

Enzyme Replacement Therapy

Drug notes:

Also Clin1/Clin2 ABCC6 deficiency, Clin0 calciphylaxis, RD neointimal proliferation diseases; undisclosed RD/Clin0 mineralization disorders

Long description:

Inozyme Pharma is a clinical-stage biopharmaceutical company developing therapies for patients with rare mineralization disorders. The company's unique science is based on its proprietary platform for the development of enzyme replacement therapies that use engineered enzymes to treat lysosomal storage disorders. Inozyme Pharma's lead product candidate, INZ-701, is an enzyme replacement therapy for the treatment of ENPP1 Deficiency and ABCC6 Deficiency, two rare disorders that cause abnormal mineralization of bones, teeth, and other tissues. INZ-701 is an engineered enzyme that replaces the missing or deficient ENPP1 or ABCC6 enzyme and restores normal mineralization.